Image may be NSFW.
Clik here to view.
Men love being admired in the bedroom. While most women are first drawn to feel being “the one” for their partner, being mutually attached and emotionally connected to their man, then being loved, men’s prerequisites are based on the sense of physical pleasure, sexual arousal, and orgasm.
It is after the intercourse that the language of the so-called love is more understood by the hombre in the bedroom. However, the bedroom is not at all an inviting place for some men. Instead, it is a place of worries and fears.
Moreover, although it is a topic for which a major part of the masculine population deems not to discuss openly in the society or even within the walls of a doctor’s clinic, sexual dysfunction is a reality. One of the causes of this is impotence or erectile dysfunction.
Sexual impotence, erectile dysfunction, or ED, is defined as the disability to develop or maintain erection therefore failure to penetrate the vagina during intercourse.
It has different causes that are generally physiological and health related or psychological reasons rooted to the emotional state of the patient. Statistical data shows that this is experienced by 10% of the male population. And as the age bracket goes higher, the statistics of cases for this physical disorder goes up.
The patient either undergoes disorders in having the desire to perform intercourse, failure to be aroused by the partner, delay or no orgasm at all, and experiencing pain during contact.
Thankfully, with the fast-paced advancement in the different branches of science and technology, men have various choices to address this problem.
New impotence treatments are continuous subject of medical researches and new hopes are given to the masculine population. The goal of which is to develop treatments that are not painful, has less side effects, and take effect more quickly.
One of this is the introduction of new erectile dysfunction drugs to market that could be taken by patients with the prescription of his physician. The list includes drugs having Alprostadil, Apomorphine, phoshodiesterase inhibitors, and Melanocortin activators as its main active ingredients.
Prostaglandin pharmaceutically known as Alprostadil is a vasodilator that comes with the brand name Caverject, Caverject Impulse, Edex, Muse. Medicines under this group increase blood flow by widening the blood vessels as the muscles relax.
When there is increased blood flow in the penis, erection is achieved. One of the classical methods of introducing Alprostadil to the male organ is through injection.
Known example is the practice of injecting Caverject at the Corpus Cavernosum, which is the side of the penis.
Although the method is painless and erection takes place 5 to 10 minutes after the injection, administration of the drug is not advisable for men with hypertension, those with penis deformities, patients with penile implants, or those who are restricted by their physician to undergo sexual activity.
This drug is also found out to cause penile fibrosis also called Peyronie’s disease. Symptoms observed on male organs with penile fibrosis include inflammation, presence of scars, lumps, bent penis, or even painful erections.
Also, injection of the drug reportedly causes prolonged erection or priapism that only a small dosage is advised. In this more advanced generation, Topiglan is developed to take away the burden of taking the drug by injection. It is used as topical cream rubbed at the tip of the male’s organ that stimulates the penis just the same.
Although the application of Topiglan is not all successful to hundred percent of tested patient and some claims its ineffectiveness, there are still some studies saying that the majority of those men that underwent the test achieved erection sufficient to perform intercourse.
At present, the use of the drug is not yet approved by the Food and Drugs Administration (FDA).Past researches and development for the said drug originated at MacroChem Corporation.
Added to the list of new erectile dysfunction drugs to market has the active ingredient Apomorphine. This chemical, a derivative of Aporphine, targets the brain’s dopamine receptor in the hypothalamus.
The stimulation of this part of the brain serves as the new impotence treatment as it enhances sexual response. As the dopamine receptor is induced, signals are transmitted to the sacral parasympathetic nucleus from the spinal cord followed by the stimulation of the sacral nerves supplying the penis. Erection is caused by the flow of blood as the penis muscles relax and the arteries dilate.
The drug is marketed with the trade names Ixense — and more currently as Uprima — by Abbott pharmaceutical company. Uprima is administered sublingually about 20 minutes before sexual activity; it enters the body through the tissues under the tongue.
Sublingual administration of drugs is more direct therefore the threat of being degraded before reaching the blood stream is avoided resulting to a faster effect.
However, the drug is to be taken with precautions because of observed side effects such as headache, dizziness, nausea, vomiting, or even fainting. Uprima is widely available in European markets. Currently, Apomorphine drugs are clinically utilized for the treatment of Parkinson’s disease.